News

Prior to joining the company, Berenson served as president and CEO at HemaQuest Pharmaceuticals and as founder, director, president and CEO at Xcyte Therapies. He also served as

According to the deal, Myriad will perform protein biomarker discovery on over 8,000 serum samples collected from patients with pre-diabetes or Type 2 Diabetes participating in Glargine Intervention

Located in Nashville, the expanded facility provides additional wet lab, office and storage space to current and prospective tenants. CET and Cumberland Pharmaceuticals chief executive officer A.J. Kazimi

The medicines resulting from the collaboration will inhibit the activity of protein that is wrongly expressed by the DUX4 gene and causes progressive muscle weakness and atrophy in

The new office staff, which includes bilingual Mandarin/English speakers, will initially be responsible for supporting clinical studies using ClinPhone randomization and trial supply management (RTSM) and Datalabs EDC

The solution offers data resources and analytical tools which are pre-loaded onto the Sage-N Research iDA, enhancing internal data with semantically integrated public reference resources. Sentient iDA will

Both the parties will work together to strenthen the commercial position of Probi brand in the region. Probi CEO Michael Oredsson said the agreement is an important opportunity

The facility follows BASF’s acquisition of controlling stake in Lewis based Equateq, a technology company in lipid chemistry and pharmaceutical omega-3 fatty acid production. Scotland First Minister, Alex

Studies primary investigator George Peoples said new treatment options are needed to address unmet medical needs for breast cancer patients with HER2 low-to-intermediate expression or IHC 1+/2+ disease.